Evidence map›Paper›PMID 31481497›Full record

ArticleCancer research2019

Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells.

Tsukasa Shibue, Ferenc Reinhardt, Robert A Weinberg

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Syndecan-1 (CD138), Carcinomas and EMT.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Tsukasa ShibueWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Ferenc ReinhardtWhitehead Institute for Biomedical Research, Cambridge, Massachusetts.
Robert A WeinbergWhitehead Institute for Biomedical Research, Cambridge, Massachusetts. weinberg@wi.mit.edu.
IIT@MIT · USWhitehead Institute for Biomedical Research · US

Funding

Use of Organotypic and Mammary Gland Models to Investigate the Outcomes of ClonalP01CA080111 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI DILLON, DEBORAH · 1999 to 2018
$36.0M
Induced Differentiation to Deplete CSCs from Breast CancerR01CA078461 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEINBERG, ROBERT A · 1999 to 2017
$8.5M
Epi-genetic Programs in Cancer ProgressionR35CA220487 · NCI · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI WEINBERG, ROBERT A · 2017 to 2023
$7.3M
NCI NIH HHS P01 CA080111NCI NIH HHS R01 CA078461NCI NIH HHS R35 CA220487
6 · The paper itself

Abstract

Systemic dissemination of tumor cells often begins long before the development of overt metastases, revealing the inefficient nature of the metastatic process. Thus, already at the time of initial clinical presentation, many patients with cancer harbor a myriad disseminated tumor cells (DTC) throughout the body, most of which are found as mitotically quiescent solitary cells. This indicates that the majority of DTCs fail, for still unknown reasons, to initiate rapid proliferation after entering foreign tissue, which likely contributes significantly to the inefficiency of metastasis formation. Here, we showed that extracellular matrix (ECM) components of the host parenchyma prevented proliferation of DTCs that had recently infiltrated foreign tissue by binding to syndecan receptors expressed on the surface of these cells. This led to the recruitment of the Par-3:Par-6:atypical PKC protein complex, a critical regulator of cell polarity, to the plasma membrane and release of Par-1 kinase into the cytosol. Cytosolic Par-1 bound, phosphorylated, and inactivated KSR scaffolding proteins ultimately inhibited Ras/ERK signaling and, in turn, cell proliferation. Inhibition of the syndecan-mediated signaling restored the proliferation of otherwise dormant DTCs, enabling these cells to efficiently colonize foreign tissues. Intriguingly, naturally aggressive cancer cells overcame the antiproliferative effect of syndecan-mediated signaling either by shutting down this signaling pathway or by activating a proproliferative signaling pathway that works independent of syndecan-mediated signaling. Collectively, these observations indicate that the proliferative arrest of DTCs is attributable, in part, to the syndecan-mediated ligation of ECM proteins. SIGNIFICANCE: This study identifies a novel signaling pathway that regulates the proliferative dormancy of individual disseminated tumor cells.

Indexed as

AnimalsCell Line, TumorCell MembraneCell PolarityCell ProliferationDisease Models, AnimalExtracellular MatrixExtracellular Matrix ProteinsGene Knockout TechniquesHumansMAP Kinase Signaling SystemMiceNeoplasmsProto-Oncogene Proteins p21(ras)SyndecansExtracellular Matrix ProteinsProto-Oncogene Proteins p21(ras)Syndecans

Identifiers

PMID31481497
PMCPMC7685526
OpenAlexW2972229879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.